Press releases
ENYO Pharma appoints Jeff George as Chairman to support next phase of growth and Phase 3 readiness
- Leadership transition reinforces ENYO’s strategic positioning following positive Phase 2 results with Vonafexor in Alport Syndrome
- ENYO preparing to enter Phase 3 following planned End-of-Phase 2 meeting with health authorities in Q3 2026
Lyon, France – June 2, 2026 – ENYO Pharma (“ENYO”), a clinical-stage biotechnology company developing innovative therapies for kidney diseases, today announced the appointment of Jeff George as Non-Executive Chairman of its Board of Directors.
ENYO Pharma announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m²/yr from baseline
- 73% of patients maintained albuminuria reduction three months after treatment cessation consistent with a true disease-modifying effect
- Company plans to advance vonafexor to Phase 3 in Alport Syndrome
Lyon, France – January 8, 2026 – ENYO Pharma (“ENYO”),
ENYO Pharma announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- ENYO Pharma completes €32 million Series C with new €6 million investment from Vesalius Biocapital IV
- New funds will support two additional clinical studies and expand preclinical research, including in ADPKD
- Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor in Alport syndrome confirmed for Q4 2025
Lyon, France – June 12, 2025 – ENYO Pharma (“ENYO”), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases,
ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
- The Company will initiate a Phase 2 clinical study of Vonafexor in Alport Syndrome (called “ALPESTRIA-1”) in the first half of 2024.
- Series C proceeds will fund the Phase 2 study, as well as operations and further R&D through the first half of 2026.
Lyon, France – January 3, 2024 – ENYO Pharma (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S.
ENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting
Lyon, France. November 3rd, 2021 – ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.
